Scinai Immunotherapeutics

SCNI · NASDAQ

$0.6813−$0.0687 (−9.16%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $0.75

About SCNI

Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The firm's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.

Employees: 45
Headquarters: Jerusalem
Listed: Jun 7, 2007
Sector: Health Care
Industry: Biotechnology
Website: scinai.com

Leadership

Scinai Immunotherapeutics executives
Name	Title	Since	Age
Mark Germain	—	2018	71
Amir Reichman	—	2021	46
Uri Ben-Or	—	—	52
Elad Mark	—	—	40
Tamar Ben-Yedidia	—	—	58
Jay Green	—	—	50
Samuel Moed	—	—	59
Prof. Avner Rotman	—	2005	79
Morris Laster	—	—	57
Yael Margolin	—	—	69
Adi Raviv	—	—	66
Joshua Phillipson	—	2020	—

Similar companies

Companies in the same industry as Scinai Immunotherapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.